# A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS

> **NCT05357950** · PHASE2 · COMPLETED · sponsor: **NeuroSense Therapeutics Ltd.** · enrollment: 69 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** PrimeC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05357950
- **Lead sponsor:** NeuroSense Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-31
- **Primary completion:** 2023-11-02
- **Final completion:** 2024-11-04
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357950, "A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05357950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*